Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NEK2 | P51955 | 1/20 | 0.38 |
| ▸ | EBP | Q15125 | 1/20 | 0.38 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3916099 | 0.85 | POLB (0.45) | ALDH1A1MAPTNPSR1EPHX2KMT2A | |
| SCHEMBL3916416 | 0.80 | KEAP1 (0.43) | ALDH1A1NPSR1EPHX2KMT2AMEN1 | |
| SCHEMBL3920891 | 0.69 | LMNA (0.44) | ALDH1A1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL3927361 | 0.68 | MMP2 (0.44) | ALDH1A1EPHX2KMT2AMEN1NPC1 | |
| SCHEMBL12662898 | 0.68 | CYP2D6 (0.41) | ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL3917508 | 0.67 | EBP (0.47) | ALDH1A1MAPTNPSR1EPHX2NEK2 | |
| SCHEMBL12662897 | 0.67 | CYP2D6 (0.48) | ALDH1A1KMT2AMEN1MAPK1KDM4E | |
| SCHEMBL4038204 | 0.66 | EPHX2 (0.47) | ALDH1A1EPHX2KMT2AMEN1MAPK1 | |
| SCHEMBL4038092 | 0.65 | ALDH1A1 (0.46) | ALDH1A1MAPTNPSR1KMT2AMEN1 | |
| SCHEMBL3925460 | 0.65 | ALDH1A1 (0.47) | ALDH1A1NPSR1KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | claimed |
| US-7560468-B2 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | THPO, UGT1A8, UGT1A4 | ALDH1A1 199/4885MAPT 689/4885NPSR1 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.